Sun et al. reported that sFRP2 remarkably induces transcription by the nuclear factor-κB (NF-κB) complex, and sFRP2 augments WNT16B signaling to promote advanced malignancies, particularly by achieving therapeutic resistance in the damaged tumor microenvironment [22]. Here, SFRP2 is linked to neoplasm.